> Detailanzeige

Sentís, Alexis; Kislaya, Irina; Nicolay, Nathalie; Meijerink, Hinta; Starrfelt, Jostein; Martínez-Baz, Iván; Castilla, Jesús; Nielsen, Katrine Finderup; Hansen, Christian Holm; Emborg, Hanne-Dorthe; Nardone, Anthony; Derrough, Tarik; Valenciano, Marta; Nunes, Baltazar; Monge, Susana

Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022
  • Beteiligte: Sentís, Alexis; Kislaya, Irina; Nicolay, Nathalie; Meijerink, Hinta; Starrfelt, Jostein; Martínez-Baz, Iván; Castilla, Jesús; Nielsen, Katrine Finderup; Hansen, Christian Holm; Emborg, Hanne-Dorthe; Nardone, Anthony; Derrough, Tarik; Valenciano, Marta; Nunes, Baltazar; Monge, Susana
  • Erschienen: European Centre for Disease Control and Prevention (ECDC), 2022
  • Erschienen in: Eurosurveillance, 27 (2022) 30
  • Sprache: Englisch
  • DOI: 10.2807/1560-7917.es.2022.27.30.2200551
  • ISSN: 1560-7917
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65–79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant.
  • Zugangsstatus: Freier Zugang